Published ahead of print on March 11, 2005, doi:10.1164/rccm.200409-1243OC
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 1312-1316, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200409-1243OC
The Effect of Primary Graft Dysfunction on Survival after Lung Transplantation
Jason D. Christie,
Robert M. Kotloff,
Vivek N. Ahya,
Gregory Tino,
Alberto Pochettino,
Christina Gaughan,
Ejigayehu DeMissie and
Stephen E. Kimmel
Divisions of Pulmonary and Critical Care Medicine and Cardiovascular Medicine, Department of Medicine; Department of Biostatistics and Epidemiology; and Division of Thoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Correspondence and requests for reprints should be addressed to Jason D. Christie, M.D., M.S., Assistant Professor of Medicine and Epidemiology, Division of Pulmonary, Allergy, and Critical Care Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 423 Guardian Drive, 719 Blockley Hall, Philadelphia, PA 19104. E-mail: jchristi{at}cceb.med.upenn.edu
Rationale: Primary graft dysfunction is a severe acute lung injury syndrome after lung transplantation. Long-term outcomes of subjects with primary graft dysfunction have not been studied. Objectives: We sought to test the relationship of primary graft dysfunction with both short- and long-term mortality using a large registry. Methods: We used data collected on 5,262 patients in the United Network for Organ Sharing/International Society of Heart and Lung Transplantation registry between 1994 and 2000. We assessed outcomes in all subjects; to assess potential bias from the effects of early mortality, we also evaluated subjects who survived at least 1 year, using Cox proportional hazards models with time-varying covariates. Main Results: The overall incidence of primary graft dysfunction was 10.2% (95% confidence intervals [CI], 9.2, 10.9). The incidence did not vary by year over the period of observation (p = 0.22). All-cause mortality at 30 days was 42.1% for primary graft dysfunction versus 6.1% in patients without graft dysfunction (relative risk = 6.95; 95% CI, 5.98, 8.08; p < 0.001); among subjects who died by 30 days, 43.6% had primary graft dysfunction. Among patients surviving at least 1 year, those who had primary graft dysfunction had significantly worse survival over ensuing years (hazard ratio, 1.35; 95% CI, 1.07, 1.70; p = 0.011). Adjustment for clinical variables including bronchiolitis obliterans syndrome did not change this relationship. Conclusion: Primary graft dysfunction contributes to nearly half of the short-term mortality after lung transplantation. Survivors of primary graft dysfunction have increased risk of death extending beyond the first post-transplant year.
Key Words: acute lung injury lung transplantation outcomes primary graft dysfunction reperfusion injury
This article has been cited by other articles:

|
 |

|
 |
 
J. B. Orens and E. R. Garrity Jr.
General Overview of Lung Transplantation and Review of Organ Allocation
Proceedings of the ATS,
January 15, 2009;
6(1):
13 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Lee and J. D. Christie
Primary Graft Dysfunction
Proceedings of the ATS,
January 15, 2009;
6(1):
39 - 46.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Belperio, S. S. Weigt, M. C. Fishbein, and J. P. Lynch III
Chronic Lung Allograft Rejection: Mechanisms and Therapy
Proceedings of the ATS,
January 15, 2009;
6(1):
108 - 121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. I. Sternberg, R. Gowda, D. Mehra, W. Qu, A. Weinberg, W. Twaddell, J. Sarkar, A. Wallace, B. Hudson, F. D'Ovidio, et al.
Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice
J. Thorac. Cardiovasc. Surg.,
December 1, 2008;
136(6):
1576 - 1585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Iwata, A. Philipovskiy, A. J. Fisher, R. G. Presson Jr., M. Chiyo, J. Lee, E. Mickler, G. N. Smith, I. Petrache, D. B. Brand, et al.
Anti-Type V Collagen Humoral Immunity in Lung Transplant Primary Graft Dysfunction
J. Immunol.,
October 15, 2008;
181(8):
5738 - 5747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ferraro, J. Martin, J. Dery, J. Prenovault, L. Samson, M. Coutu, L.-Q. Chen, C. Poirier, N. Noiseux, A. Duranceau, et al.
Late retrograde perfusion of donor lungs does not decrease the severity of primary graft dysfunction.
Ann. Thorac. Surg.,
October 1, 2008;
86(4):
1123 - 1129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kohmoto, A. Nakao, R. Sugimoto, Y. Wang, J. Zhan, H. Ueda, and K. R. McCurry
Carbon monoxide-saturated preservation solution protects lung grafts from ischemia-reperfusion injury.
J. Thorac. Cardiovasc. Surg.,
October 1, 2008;
136(4):
1067 - 1075.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gottlieb
Review: Update on lung transplantation
Therapeutic Advances in Respiratory Disease,
August 1, 2008;
2(4):
237 - 247.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Prekker, C. S. Herrington, M. I. Hertz, D. M. Radosevich, and P. S. Dahlberg
Early Trends in PaO2/Fraction of Inspired Oxygen Ratio Predict Outcome in Lung Transplant Recipients With Severe Primary Graft Dysfunction
Chest,
September 1, 2007;
132(3):
991 - 997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Daud, R. D. Yusen, B. F. Meyers, M. M. Chakinala, M. J. Walter, A. A. Aloush, G. A. Patterson, E. P. Trulock, and R. R. Hachem
Impact of Immediate Primary Lung Allograft Dysfunction on Bronchiolitis Obliterans Syndrome
Am. J. Respir. Crit. Care Med.,
March 1, 2007;
175(5):
507 - 513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Burton, M. Iversen, N. Milman, M. Zemtsovski, J. Carlsen, D. Steinbruchel, J. Mortensen, and C. B. Andersen
Outcome of lung transplanted patients with primary graft dysfunction
Eur. J. Cardiothorac. Surg.,
January 1, 2007;
31(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Christie, N. Robinson, L. B. Ware, M. Plotnick, J. De Andrade, V. Lama, A. Milstone, J. Orens, A. Weinacker, E. Demissie, et al.
Association of Protein C and Type 1 Plasminogen Activator Inhibitor with Primary Graft Dysfunction
Am. J. Respir. Crit. Care Med.,
January 1, 2007;
175(1):
69 - 74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Mason, D. J. Boffa, S. C. Murthy, T. R. Gildea, M. M. Budev, A. C. Mehta, A. M. McNeill, N. G. Smedira, J. Feng, T. W. Rice, et al.
Extended use of extracorporeal membrane oxygenation after lung transplantation
J. Thorac. Cardiovasc. Surg.,
October 1, 2006;
132(4):
954 - 960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Medoff, J. C. Wain, E. Seung, R. Jackobek, T. K. Means, L. C. Ginns, J. M. Farber, and A. D. Luster
CXCR3 and Its Ligands in a Murine Model of Obliterative Bronchiolitis: Regulation and Function.
J. Immunol.,
June 1, 2006;
176(11):
7087 - 7095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Estenne and R. M. Kotloff
Update in transplantation 2005.
Am. J. Respir. Crit. Care Med.,
March 15, 2006;
173(6):
593 - 598.
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|